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Summary
Background: Obesity is a common feature of equine metabolic syndrome (EMS). In other species, obese adipose tissue shows pathological features
such as adipocyte hypertrophy, fibrosis, inflammation and impaired insulin signalling all of which contribute to whole body insulin dysregulation. Such
adipose tissue dysfunction has not been investigated in horses.
Objectives: To determine if obese horses with EMS have adipose tissue dysfunction characterised by adipocyte hypertrophy, fibrosis, inflammation
and altered insulin signalling.
Study design: Cross-sectional post-mortem study.
Methods: Samples of peri-renal (visceral) and retroperitoneal adipose tissue were obtained at post-mortem from healthy horses (n = 9) and horses with
EMS (n = 6). Samples were analysed to determine average adipocyte size, fibrotic content and expression of inflammatory and insulin signalling genes.
Results: Horses with metabolic syndrome showed marked adipocyte hypertrophy and increased expression of adipokines (leptin) and inflammatory
cytokines (TNFa, IL1b and CCL2) in both adipose tissue depots compared to healthy horses. There were no differences in fibrosis or expression of genes
relating to insulin signalling between the groups.
Main limitations: Cases used in this study had advanced EMS and may represent the end stage of the condition; the design of the study is such that
we were unable to relate the identified adipose tissue dysfunction to whole body insulin dysregulation.
Conclusions: Horses with obesity and EMS have significant dysfunction of the peri-renal and retroperitoneal adipose tissue that may contribute to
whole body insulin dysregulation.
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Introduction
Equine metabolic syndrome (EMS), defined as a collection of risk factors
including insulin dysregulation, genetic predisposition and obesity which
increase the animal’s susceptibility to laminitis, is common in domesticated
horses [1]. The increased risk of laminitis conferred by the presence of EMS
makes this condition a significant welfare problem [2]. Obesity, defined as
excessive fat accumulation which may impair health, is a key feature of
EMS in the majority of reported cases, but little is known about the
pathology of obese adipose tissue in EMS.
Adipose tissue expands in response to calorie intake in excess of
nutritional requirements either by increasing adipocyte number (hyperplasia)
or increasing adipocyte size (hypertrophy) [3]. In humans and dogs,
hypertrophy of adipocytes is associated with whole body insulin resistance
and elevated fasting plasma insulin [4,5], whilst hyperplasia appears to be a
protective phenotype associated with better insulin sensitivity and lipid
profiles [6]. Human obese adipose tissue is also characterised by increased
fibrosis [7], infiltration of macrophages and a pro-inflammatory phenotype
[8,9]. The adipose tissue can itself become resistant to the effects of insulin
but probably more significantly obese adipose tissue can contribute to
whole body insulin resistance though the release of free fatty acids, pro-
inflammatory cytokines and adipokines [10].
Obese adipose tissue in horses also shows signs of dysfunction including
signs of impaired mitochondrial function [11], altered insulin signalling [11],
enhanced glucocorticoid metabolism [12]. Other indications of adipose
tissue dysfunction in obese horses include an altered plasma lipidome [13]
and elevated plasma leptin concentrations [14]. A pro-inflammatory
phenotype is not consistently reported in adipose tissue of horses with
obesity, insulin dysregulation or EMS [15–17] though correlations between
circulating inflammatory cytokines and adiposity are reported [16,18,19].
In this study, we aimed to further investigate obese adipose tissue in the
horse. We focus on intra-abdominal adipose tissue depots which are
associated with the most pathological changes and associated morbidities
in other species [20] and which expand rapidly in horses with obesity. We
hypothesised that obese horses with EMS have visceral and retroperitoneal
adipose tissue dysfunction characterised by adipocyte hypertrophy,
fibrosis, inflammation and altered insulin signalling.
Materials and methods
Horses
Healthy horses and horses with EMS, destined for euthanasia, were
recruited from clinics at the Royal (Dick) School of Veterinary Studies.
Healthy horses were defined as those with no clinical (body condition score
<4/5, no history or evidence of laminitis), histological (pituitary score <3/5)
or biochemical evidence of endocrine disease (fasting basal insulin
<20 mIU/L, plasma ACTH within the seasonal reference range) and no
history of glucocorticoid administration within the previous 3 months.
Horse with EMS were defined as those >2 years of age of a susceptible
breed (native British breeds) with a body condition score ≥4/5 [21], fasting
basal insulin >20 mIU/L [1], current or historical laminitis, plasma ACTH
within the seasonal reference range [22] and a pituitary histological
score <3/5 [23]. ACTH and insulin concentrations were measured by
chemiluminescent immunoassays (Immulite 2000)a. Horses were humanely
subjected to euthanasia with quinalbarbitone sodium and cinchocaine
hydrochloride (1 mL/10 kg bodyweight; Somulose)b. Samples of peri-renal
and retroperitoneal (lying deep to the linea alba) adipose tissue were
collected and bisected, half was fixed in 10% paraformaldehyde overnight
and half snap frozen and stored at80°C.
This is an open access article under the terms of the Creative Commons Attribution
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Adipocyte size
Five-micrometre sections of the adipose tissue were stained with haematoxylin/
eosin. Four randomly selected images of each slide were obtained (Olympus
BX51) at 49 magnification. The images were validated manually and a
minimum of three were analysed using Image J software with
the Adiposoft v1.13 plugin [24] to determine cell area, the average of
all the images was taken to given the final average adipocyte area (lm2).
Adipose fibrosis
Sections (5 lm) of adipose tissue were stained for collagen with Picrosirius
red (PSR). Whole slide scanning was performed at 59 viewing
magnification using a Zeiss Axio Scannerc. Scanned images were manually
checked. Staining was analysed using Fiji imaging software (Image J). Total
fibrosis was expressed as the ratio of stained area to total tissue surface as
previously described [25].
Gene expression
Adipose tissue was homogenised in Qiazold. Total RNA was extracted using
the RNAeasy Mini Kite. RNA quality was assessed using a Nanodrop
TABLE 1: Clinical and biochemical characteristics of the study
groups
Healthy (n = 9) EMS (n = 6) P value
Age (years) 17.4  2.3 18.8  1.6 0.1
Breed 4 Thoroughbreds,
2 Welsh Cob X Thoroughbred,
2 Irish Sports Horses,
1 Trakhener X Thoroughbred
4 Welsh cobs,
1 Shetland,
1 Icelandic
Horse)
Body condition
score (/5)1
2 (IQR 1.75–2.0) 4.5 (IQR 4–5) <0.001
Fasting insulin
(mIU/L)
7.1  4.5 51.4  15.8 <0.001
ACTH
(pg/mL)
34.3  4.3 34.0  5.7 0.9
Data are mean  s.e.
1The body condition score (BCS, /5) as a measure of adiposity (Carroll
and Huntington [21]), Comparisons between groups were by Student’s T
test or Mann-Whitney U test. *P<0.05 vs. healthy group.
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Fig 1: Mean adipocyte area in peri-renal and retroperitoneal adipose tissue of healthy horses and horses with equine metabolic syndrome (EMS). Graphs showing the
mean (s.e.) adipocyte area (lm2) in peri-renal a) and retroperitoneal b) adipose tissue of healthy horses and horses with EMS. *P<0.05. Representative micrographs of
peri-renal adipose from a healthy horse c) and a horse with EMS d) (920 magnification). Adipocytes were significantly larger in the peri-renal and retroperitoneal depots
of horses with EMS compared with healthy controls.
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Spectrometer. Five hundred-nanogram of RNA was reverse transcribed
using Quantitect Reverse Transcription Kitf to synthesise cDNA.
Quantitative real-time polymerase chain reaction was performed using a
Light-cycler 480g. The most appropriate housekeeping genes for each tissue
were determined by testing six candidates and using NormFinder software
(MOMA, Arhaus University Hospital, Denmark) [26]; for both depots these
were 18s and succinate dehydrogenase (SDHA). Target gene expression was
arbitrarily quantified against a standard curve constructed from pooled
samples for each primer probe combination corrected by two housekeeping
genes. Expression of genes associated with fibrosis (collagen 1a, hypoxia
inducible factor 1a, smooth muscle actin), macrophage recruitment
(chemokine [C-C motif] ligand 2, also referred to as monocyte chemoattractant
protein 1) inflammation (tumour necrosis factor a, interleukin 1b), adipokine
release (leptin, adiponectin) and insulin signalling (insulin receptor, insulin
receptor substrate 1, mammalian target of rapamycin, mTOR) was analysed.
See Supplementary Item 1 for primer sequences.
Data analysis
Based on preliminary data, a power calculation determined that five horses
per group would give 85% power to detect a 50% increase in average
adipocyte size (healthy 5000 lm2  2500 vs. EMS 7500 lm2  2500).
Statistical analysis was performed using Graph Pad Prism 5h and SPSS
statistics 19i. Data were tested for normality using a Kolmogorov-Smirnov
test. Data from the two groups were analysed using a Student’s t test or
Mann-Whitney test as appropriate. Data were also analysed by two-way
ANOVA for the effect of adipose tissue depot. Significance was set at
P<0.05. Data are presented as mean (s.e.).
Results
Nine healthy horses and six horses with EMS were recruited to the study.
Table 1 shows their clinical characteristics.
Adipocyte size
Adipocytes from horses with EMS from both the peri-renal (healthy
5818  1494 vs. EMS 12481  2758 lm2 P = 0.004) and retroperitoneal
depots (healthy 4751  1406 vs. EMS 16621  3082 lm2, P = 0.002)
were significantly larger than those from healthy horses (Fig 1). Adipose
tissue depot had no significant effect on adipocyte size.
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Fig 2: Adipose fibrosis in peri-renal and retroperitoneal adipose tissue of healthy horses and horses with equine metabolic syndrome (EMS). Graphs showing the mean
(s.e.) picrosirius red (PSR) staining expressed as a percentage of the total section area in peri-renal a) and retroperitoneal b) adipose tissue from healthy horses and
horses with EMS. Representative micrographs of peri-renal adipose from a healthy horse c) and a horse with EMS d) showing PSR staining (95 magnification). There were
no differences in the percentage of PSR staining of the peri-renal or retroperitoneal adipose depots between healthy horses and those with EMS.
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Adipose fibrosis
Picrosirius red staining was not significantly different between healthy
horses and horses with EMS (Fig 2). Adipose tissue depot had no
significant effect on the quantity of staining.
Adipose tissue gene expression
Adipokines: Leptin expression was significantly higher in both peri-renal
(P = 0.01) and retroperitoneal (P = 0.005) adipose tissue from horses with
EMS compared with healthy horses. Adiponectin expression was not
different between the groups in either depot (Figs 3, 4). Adipose tissue
depot had no significant effect on expression.
Adipose tissue morphology
There was no difference in expression of collagen 1a, the predominant
component of fibrotic tissue or HIF1a, an inducer of fibrosis, between the
groups in either depot. Blood vessel marker smooth muscle actin
expression was also not different between the groups in either depot
(Supplementary Items 2 and 3). Adipose tissue depot had no significant
effect on expression.
Insulin signalling
None of the candidate genes related to insulin signalling (IR, IRS1 and
mTOR) were differentially expressed between the groups in either adipose
tissue depot (Supplementary Items 2 and 3). Adipose tissue depot had no
significant effect on expression.
Inflammation
Expression of inflammatory cytokines TNFa (P = 0.001) and IL1b (P = 0.01)
was higher in peri-renal adipose tissue from horses with EMS compared
with healthy horses. TNFa (P = 0.008) but not IL1b (P = 0.06) was higher in
0
Leptin Adiponectin
Healthy
EMS
Peri-renal adipose
2
3
1
4
*
* *
*
5
6
0
TNFα IL1β CCL2
2
3
m
R
N
A
 tr
an
sc
ri
p
t l
ev
el
s
m
R
N
A
 tr
an
sc
ri
p
t l
ev
el
s
1
4
5
6
a)
b)
Fig 3: Peri-renal adipose gene expression in healthy horses and horses with EMS.
Graphs showing peri-renal adipose mRNA transcript levels of adipokines, leptin
and adiponectin (a) and inflammatory cytokines tumour necrosis factor a (TNFa),
interleukin 1b (IL1b) and chemokine (C-C motif) ligand 2 (CCL2). (b) Transcript
levels are expressed as a ratio to housekeeping genes 18s and succinate
dehydrogenase. *P<0.05.
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Retroperitoneal adipose
Fig 4: Retroperitoneal adipose gene expression in healthy horses and horses
with equine metabolic syndrome. Graphs showing retroperitoneal adipose mRNA
transcript levels of adipokines, leptin and adiponectin (a) and inflammatory
cytokines tumour necrosis factor a (TNFa), interleukin 1b (IL1b) and chemokine
(C-C motif) ligand 2 (CCL2). (b) Transcript levels are expressed as a ratio to
housekeeping genes 18s and succinate dehydrogenase. *P<0.05.
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retroperitoneal adipose tissue from horses with EMS compared with
healthy horses. CCL2, a monocyte chemoattractant, was significantly higher
in both depots (peri-renal P = 0.007, retroperitoneal P = 0.02) in horses
with EMS compared with healthy horses (Figs 3, 4). Adipose tissue depot
had no significant effect on expression.
Discussion
In this study, we hypothesised that adipose tissue from horses with metabolic
syndrome would be dysfunctional with adipocyte hypertrophy, fibrosis,
inflammation and altered insulin signalling. Our data demonstrate that
adipocyte hypertrophy, inflammation and increased CCL2 expression are
features of obese adipose tissue in horses but that fibrosis and altered adipose
tissue expression of insulin signalling genes are not consistent features.
Increased adipocyte size, hypertrophy, in response to excess calorie
intake is associated with insulin resistance and dyslipidaemia in humans
whereas increasing adipocyte number, hyperplasia, is associated with a
favourable metabolic profile [3]. Hypertrophy occurs when there is an
imbalance between lipid storage and lipolysis. Defects in lipolysis can occur
secondary to insulin resistance but equally engorgement of adipocytes with
excess lipid leads to dysfunction of the adipose tissue which can contribute
to whole body insulin dysregulation for example through release of free fatty
acids, adipokines and cytokines [10]. In a canine model of induced obesity,
adipocyte size in the visceral depot was a strong predictor of whole body
insulin resistance and the authors concluded that hypertrophy developed
first and played a key role in the development of insulin resistance [5]. In our
study, we demonstrate that obese horses with EMS display marked
adipocyte hypertrophy and this is accompanied by inflammation. The horses
in this study have resting hyperinsulinaemia, but we cannot say for certain
whether the hypertrophic nature of the adipose tissue is a cause or a
consequence of insulin dysregulation in these animals. Equally, we have not
established whether obese horses always have hypertrophy or whether it is
only hypertrophied when associated with insulin dysregulation.
While circulating inflammatory cytokines are fairly consistently elevated
in horses with obesity and/or insulin dysregulation, studies of adipose
tissue have generally been less consistent, though most studies have used
subcutaneous depots [15–18]. Similar to other species [27], adipocyte
hypertrophy in horses in this study was accompanied by increased
expression of the adipokine leptin and the inflammatory cytokines TNFa,
IL1b and CCL2. CCL2, also known as monocyte chemoattractant protein-1,
mediates macrophage infiltration into adipose tissue [28]. Obesity in
humans and mice is known to induce a pro-inflammatory phenotype in
resident adipose tissue macrophages as well as inducing macrophage
recruitment [29]. Macrophages are the main source of TNFa and IL1b.
TNFa in particular is known to induce changes within adipocytes which
have harmful effects on whole body insulin signalling; for example, TNFa
increases lipolysis causing free fatty acid release, decreases peroxisome
proliferator activated receptor-gamma (PPARc) expression and has direct
actions on muscle insulin signalling [30]. As such macrophages have been
identified as a therapeutic target in treating insulin resistance in humans
[31] and our data suggest they may also be important in EMS.
Leptin gene expression was also markedly increased in the adipose tissue
of horses with EMS, a finding which is in agreement with other studies
reporting increased plasma leptin concentrations in EMS and in induced
obesity [13,32]. Adipocyte volume is the predominant determinant of leptin
expression in adipose tissue in other species [33] as such leptin may be a
marker of adipocyte hypertrophy and not just adiposity per se. Adiponectin
is also inversely proportional to adipocyte size but the relationship is not as
well characterised as that of leptin [27]; in our study there was no difference
in adiponectin expression in obese adipose tissue from horses.
Increased fibrosis was not a significant feature in the depots we studied.
While fibrosis of subcutaneous adipose tissue is associated with poor
glucose control and deleterious lipid profiles in humans, fibrosis of omental
adipose tissue appears to limit adipocyte hypertrophy and is associated
with better glucose and lipid control [7]. Less work has been carried out in
other species though upregulation of extracellular matrix genes is reported
in induced obesity in dogs [34]. While our study was adequately powered
to detect a difference in adipocyte size, a retrospective power calculation
shows that it was insufficiently powered to detect subtle differences in PSR
staining due to the variability within the groups (38 horses per group
would be required to give 85% power to detect a difference in groups;
healthy 3.79%  2.17% vs. EMS 4.46%  3.35%); despite this it seems clear
that hypertrophy and not fibrosis is the hallmark feature of obese adipose
tissue in horses.
The relationship between adipose tissue dysfunction and insulin resistance
is a complex and poorly understood one. Adipose tissue itself can be insulin
resistant but most now argue that the pathological changes to the adipose
tissue which contribute to whole body insulin dysregulation such as
adipokine and cytokine release are more significant [35]. In this study, we did
not identify any significant differences in expression of the candidate genes
relating to insulin signalling that we chose to analyse. Marycz et al. [11]
reported increased insulin receptor and IRS expression in subcutaneous
adipose tissue of Polish warmbloods with EMS, our conflicting data may
therefore be due to the different depots we chose to study. There are clear
depot-specific differences in insulin signalling and gene expression in humans
and horses [36–38]. It should be noted that this candidate gene approach for
assessing insulin signalling is very limited given the vast number of genes
and the dynamic nature of insulin signalling and it tells us little about function
which is generally governed by phosphorylation events.
As with any clinical study, our data are from a diverse range of horses
with varying degrees of disease the duration of which was not
documented; as such we are limited in our ability to draw conclusions in
terms of cause and effect. Further studies in models of induced equine
obesity are necessary to further define the relationship between adipose
tissue dysfunction and insulin dysregulation and critically define the time
point in weight gain when adipose tissue becomes ‘unhealthy’. Our
inclusion criteria dictated that those horses in the EMS group were
genetically predisposed that is native breeds for example, Welsh ponies.
As such the breed distribution was very different between the groups
and we cannot rule out breed effects on adipocyte size and expression
profile. However, human twin studies suggest that while the hyperplastic
response to excess calorie intake is largely genetically determined the
hypertrophic response is less so [39]. There were no differences in age
between the groups in our study, they were all mature. In other species,
advancing age is associated with a reduction in adipocyte area and an
increase in fibrosis [40], further work is required to understand the
effects of age on equine adipose tissue. We only included horses that
had obesity and EMS in this study, whilst this represents the majority of
EMS cases, horses that are apparently lean but with insulin dysregulation
are described [1], we cannot rule out inadvertent inclusion of such
horses in our healthy control group.
Nuchal crest adipose and rump adipose tissue are often studied as
subcutaneous adipose depots in horses [41]; in our experience the fibrosis
within the nuchal crest depot is so extensive that this masks adipocyte-
specific pathology and in lean horses getting a representative sample of
adipose tissue is often technically challenging. Rump subcutaneous
adipose tissue often contains muscle fibres and presents similar problems
[17], as such we chose to focus on visceral and retroperitoneal depots
which are associated with the most adverse effects in other species [20]
and which expand rapidly in horses with obesity. We chose to use peri-
renal adipose tissue as our visceral depot of choice as it is consistently
present even in very lean horses, study of omental, mesenteric and peri-
cardial adipose tissue depots would be a useful extension to our work.
In conclusion, we have demonstrated that visceral and retroperitoneal
adipose tissue of horses with obesity and EMS is markedly dysfunctional
with a hypertrophic-inflammatory phenotype. In educating owners about
EMS, it is important to emphasise the ‘unhealthy’ nature of obese adipose
tissue and its effects on the rest of the body, particularly in potentially
inducing or worsening whole body insulin dysregulation.
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